Option chain shows key data for Brookfield's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Brookfield.

Brookfield (OTC:BRPSF) Stock, Option Chain

Brookfield Corp is an investment firm focused on building long-term wealth for institutions and individuals. It has three businesses Asset Management, Insurance Solutions, and Operating Businesses. it invests in real assets that form the backbone of the economy to deliver risk-adjusted returns to stakeholders. It generates the majority of its revenue from Asset Management. It has a geographic presence in the UK, the United States, Australia, Canada, Brazil, India, and other countries.

4.75 % Cum Conv Pfd Registered Shs -A- Series 17

BROOKFIELD CP PREF A 17 by BROOKFIELD CORP.

Brookfield Corp

The Department of Government Efficiency has opened its official X account with the <a href="https://benzinga.com/topic/department-of-government-efficiency">username DOGE</a>, which in addition to being the acronym of the name of the department, is also a reference to the cryptocurrency Dogecoin.
What Happened: The newly created department, it said in an X post, is aimed at ensuring &#8220;tax dollars will be spent wisely.&#8221; 
President-elect Donald Trump said earlier this week that the department will be led by billionaire Elon Musk and former Republican presidential candidate Vivek Ramaswamy. The department, he said, will be aimed at bringing down government bureaucracy, slashing excess regulations, cutting waste expenditures, and restructuring federal agencies. 
Trump also said in his statement that the department will provide advice and guidance from &#8220;outside the government,&#8221; likely implying that Ramaswamy and Musk&#8217;s appointments will not require the approval of the Senate. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Working overtime to ensure your tax dollars will be spent wisely!
&mdash; Department of Government Efficiency (@DOGE) <a href="https://twitter.com/DOGE/status/1856783252071354727?ref_src=twsrc%5Etfw">November 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Neither will get paid for their role in the department, Musk said on Thursday on X in a reply to Senator Elizabeth Warren.
&#8220;Unlike you, neither of us are being paid, so it is very efficient indeed. DOGE will do great things for the American people. Let history be the judge,&#8221; <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41963342/elizabeth-warrens-sarcastic-take-on-doges-split-leadership-gets-slammed-by-elon-musk-unlike-you-neither-of-us-are-being-paid">Musk wrote</a>.
The work of the DOGE department, Trump said earlier this week, is scheduled to conclude no later than July 4, 2026.
Why It Matters: Musk said as early as August that he discussed the idea of the department with Trump. The CEO then said that the department will be aimed at deregulation, among other things. 
"That&#8217;s (accumulation of regulations) like the hardening of the arteries. Or a way to think of it is being tied down by a million little strings like Gulliver. You can&#8217;t move. And it&#8217;s not like any one of those strings is the issue, it&#8217;s that you&#8217;ve got a million of them," <a href="https://www.benzinga.com/news/24/08/40145592/elon-musk-says-he-spoke-to-donald-trump-about-government-deficiency-commission-tesla-ceo-expresses-i">Musk then said</a> while adding that excess regulation is preventing key development projects such as building high-speed rail in the country.
Musk donated millions to Trump&#8217;s presidential campaign and actively campaigned for him both online and offline in the swing state of Pennsylvania, cementing him as a key player in Trump&#8217;s campaign and circle. 
Bill Clinton-era Secretary of Labor&nbsp;Robert Reich on Wednesday <a href="https://www.benzinga.com/politics/24/11/41962372/trumps-doge-with-musk-at-the-helm-riddled-with-conflicts-of-interest-says-clinton-era-official-robert-reich">slammed the idea of the</a> Department of Government Efficiency saying it is <a href="https://www.benzinga.com/news/24/11/41961033/gene-munster-says-elon-musks-doge-efficiency-plans-should-not-be-underestimated-but-warns-itll-likely-take-many-years-to-achieve-2-trillion-in-government-spending">not about efficiency </a>but &#8220;simply a quid-pro-quo riddled with conflicts of interest."
"Anything and everything will always be for sale under Trump. Musk is just the latest person to take advantage of this,&#8221; Reich wrote in a post on X. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41934708/tesla-recalls-over-2400-cybertrucks-in-us" target="_blank" rel="noreferrer noopener">Tesla Recalls Over 2400 Cybertrucks In US</a></li>
</ul>
Photos courtesy: Shutterstock and Gage Skidmore on Flickr

News

Politics

Elon Musk, Vivek Ramaswamy-Led Department Of Government Efficiency Opens Account On X, Says It Is 'Working Overtime'

On November 14, 2024, Zhejiang ZEEKR Intelligent Technology Co., Ltd ("Zhejiang ZEEKR"), ZEEKR's indirect wholly-owned PRC subsidiary principally engaged in the sale of vehicles, entered into an equity transfer agreement (the "LYNK &amp; CO Equity Transfer Agreement") with Geely Holding, VCI and LYNK &amp; CO, pursuant to which Zhejiang ZEEKR will acquire a 20% interest in LYNK &amp; CO from Geely Holding and a 30% interest in LYNK &amp; CO from VCI (collectively, the "Equity Transfer") at a purchase price of RMB3.6 billion and RMB5.4 billion, respectively

Reported Earlier, Zhejiang ZEEKR To Acquire 50% Stake In LYNK & CO From Geely Holding And VCI For RMB9B

Shares of DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/quote/DLO/earnings">third-quarter revenue results</a>.
DLocal reported quarterly earnings of 9 cents per share which missed the analyst consensus estimate of 11 cents per share. The company reported quarterly sales of $185.774 million which beat the analyst consensus estimate of $181.463 million.
DLocal shares jumped 18.3% to $10.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 91.1% to $0.0472 in pre-market trading after surging 32% on Wednesday.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) rose 40% to $0.0339 in pre-market trading.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) gained 35.7% to $0.0777 in pre-market trading after gaining 18% on Wednesday.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) gained 28.7% to $0.5335 in pre-market trading.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) gained 26.9% to $8.25 in pre-market trading after the company reported second-quarter results.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) climbed 25.8% to $3.34 in pre-market trading after jumping more than 92% on Wednesday.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) gained 20.5% to $21.40 in pre-market trading. Zeta Global increased its share repurchase program with $100 million buyback authorization through 2026.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) gained 17.7% to $0.5301 in pre-market trading after dipping 58% on Wednesday.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) gained 14.6% to $2.04 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) shares tumbled 27% to $2.47 in pre-market trading after the company announced a proposed public offering.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares fell 26.5% to $0.1329 in pre-market trading after jumping over 40% on Wednesday.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) declined 25.8% to $38.45 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li>Ibotta, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) shares fell 22.9% to $57.75 in pre-market trading after the company reported quarterly results.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) fell 18.7% to $0.3658 in pre-market trading after gaining around 10% on Wednesday.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) dipped 18.3% to $0.0850 in pre-market trading after the company reported a 1-for-50 reverse stock split.</li>
<li>Matinas BioPharma Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#NYSE">MTNB</a>) shares dipped 15.9% to $0.5969 in pre-market trading after falling around 5% on Wednesday.</li>
<li>ESS Tech, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) fell 13.8% to $7.68 in pre-market trading following third-quarter results.</li>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) fell 10.8% to $1.9700 in pre-market trading following third-quarter results.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 10.1% to $18.27 in today's pre-market trading. Super Micro Computer shares fell 6% on Wednesday after the company announced it was unable to file its quarterly report for the period ending Sept. 30 in a timely manner.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

BJDX

BURU

CLDI

CYCC

DBGI

EFSH

ELAB

HROW

IBTA

MTNB

QBTS

QUBT

SMCI

SVMH

TSHA

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) reported quarterly earnings of $0.08 per share. This is a 3.57 percent decrease over earnings of $0.08 per share from the same period last year. The company reported $79.84 million in sales this quarter. This is a 4.90 percent decrease over sales of $83.95 million the same period last year.

Earnings

XNET

Xunlei Q3 2024 Adj EPADS $0.0805 Down From $0.0835 YoY, Sales $79.84M Down From $83.95M YoY

HC Wainwright &amp; Co. analyst Edward White reiterates Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and maintains $22 price target.

Price Target

Reiteration

Analyst Ratings

AURA

HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and raises the price target from $27 to $34.

VRDN

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $34

Macro Economic Events

Econ #s

Economics

Eurozone Industrial Production (MoM) For September -2.0% Vs. -1.3% Est.; 1.5% (Revised) Prior

Eurozone Gross Domestic Product (QoQ) Preliminary For Q3 0.4% Vs. 0.4% Est.; 0.4% Prior

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) with a Buy and maintains $59 price target.

BHVN

HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target

Rolling out globally across the US, Germany, Italy and Spain, the new experience gives customers the ability to set up a pool in the PayPal app or online, invite friends and family to contribute, track group contributions and transfer funds to their PayPal balance to spend or withdraw.

Tech

General

PYPL

PayPal Announced A New Experience That Makes It Easy For Customers To Pool Money With Friends And Family For Group Gifts, Travel, Special Events, Or Other Shared Expenses

Eurozone Gross Domestic Product (YoY) Preliminary For Q3 0.9% Vs. 0.9% Est.; 0.9% Prior

The Company announced today that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$200 million of its publicly traded securities for the next 24 months.

Buybacks

BILI

Bilibili Board Approved A Share Buyback Program Of Up To $200M For Next 24 Months

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and raises the price target from $1.5 to $1.8.

HC Wainwright & Co. Maintains Buy on Avino Silver & Gold Mines, Raises Price Target to $1.8

Bilibili Q3 Adj EPS $0.08 Misses $0.10 Estimate, Sales $1.04B Beat $1.01B Estimate

Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) with a Buy and lowers the price target from $5 to $4.

XFOR

Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) with a Buy and maintains $30 price target.

VYGR

HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target

Piper Sandler analyst Michael Lavery upgrades Campbell Soup (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) from Neutral to Overweight and raises the price target from $47 to $56.

Upgrades

Piper Sandler Upgrades Campbell Soup to Overweight, Raises Price Target to $56

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) with a Buy and maintains $18 price target.

MURA

HC Wainwright & Co. Reiterates Buy on Mural Oncology, Maintains $18 Price Target

Mizuho analyst Haendel St. Juste maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Neutral and raises the price target from $75 to $80.

Mizuho Maintains Neutral on Agree Realty, Raises Price Target to $80

HC Wainwright &amp; Co. analyst Yi Chen reiterates Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Comments

Brookfield

Brookfield (BRPSF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga